Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling approach

General Hospital Psychiatry

Volumn 29, Issue 2, 2007, Pages 134-140

  Schmitt, Jochen ^a,b   Ford, Daniel E ^a,c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Psoriasis; Quality of life; Severity of illness Index; Structural equations modeling

Indexed keywords

ADULT; ARTICLE; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PSORIASIS; QUALITY OF LIFE; SCREENING TEST; STRESS; STRUCTURED QUESTIONNAIRE; SYMPTOMATOLOGY;

ADULT; DEPRESSION; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEALTH STATUS; HUMANS; MALE; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; STRESS, PSYCHOLOGICAL;

EID: 33847252511     PISSN: 01638343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2006.12.004     Document Type: Article

References (51)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 3 (2004) 121-128
2. Feldman S.R., Fleischer Jr. A.B., Reboussin D.M., et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 37 (1997) 564-569
3. Stern R.S., Nijsten T., Feldman S.R., et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9 (2004) 136-139
4. de Korte J., Sprangers M.A., Mombers F.M., and Bos J.D. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 9 (2004) 140-147
5. Chaudhari U., Romano P., Mulcahy L.D., et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
6. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 (2001) 248-255
7. Gordon K.B., Papp K.A., Hamilton T.K., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 (2003) 3073-3080
8. Leonardi C.L., Powers J.L., Matheson R.T., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
9. Stern R.S. A promising step forward in psoriasis therapy. JAMA 290 (2003) 3133-3135
10. Krueger G.G., Feldman S.R., Camisa C., et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. J Am Acad Dermatol 43 (2000) 281-285
11. Zachariae H., Zachariae R., Blomqvist K., et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82 (2002) 108-113
12. Markham T., Watson A., and Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol 27 (2002) 111-114
13. Fortune D.G., Main C.J., O'Sullivan T.M., and Griffiths C.E. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 137 (1997) 755-760
14. Rapp S.R., and Feldman S.R. The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life?. Dermatol Ther 17 (2004) 376-382
15. Sampogna F., Picardi A., Chren M.M., et al. Association between poorer quality of life and psychiatric morbidity in patients with different dermatological conditions. Psychosom Med 66 (2004) 620-624
16. Gupta M.A., Gupta A.K., Schork N.J., and Ellis C.N. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 56 (1994) 36-40
17. Renzi C., Picardi A., Abeni D., et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 138 (2002) 337-342
18. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994) 210-216
19. Khilij F.A., Gonzalez M., and Finlay A.Y. Clinical meaning of change in Dermatology Life Quality Index Scores. Br J Dermatol 147 Suppl. 62 (2002) 50
20. Lewis V., and Finlay A.Y. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc 9 (2004) 169-180
21. Gupta M.A., and Gupta A.K. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol 75 (1995) 240-243
22. Fortune D.G., Main C.J., O'Sullivan T.M., and Griffiths C.E. Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res 42 (1997) 467-475
23. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1 (1977) 385-401
24. Houston T.K., Cooper L.A., Vu H.T., et al. Screening the public for depression through the Internet. Psychiatr Serv 52 (2001) 362-367
25. Schulberg H.C., Saul M., McClelland M., et al. Assessing depression in primary medical and psychiatric practices. Arch Gen Psychiatry 42 (1985) 1164-1170
26. Thomas J.L., Jones G.N., Scarinci I.C., et al. The utility of the CES-D as a depression screening measure among low-income women attending primary care clinics. The Center for Epidemiologic Studies-Depression. Int J Psychiatry Med 31 (2001) 25-40
27. Beekman A.T., Deeg D.J., Van Limbeek J., et al. Criterion validity of the Center for Epidemiologic Studies Depression Scale (CES-D): results from a community-based sample of older subjects in The Netherlands. Psychol Med 27 (1997) 231-235
28. Parikh R.M., Eden D.T., Price T.R., and Robinson R.G. The sensitivity and specificity of the Center for Epidemiologic Studies Depression Scale in screening for post-stroke depression. Int J Psychiatry Med 18 (1988) 169-181
29. Feldman S.R., Fleischer Jr. A.B., Reboussin D.M., et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 106 (1996) 183-186
30. Feldman S.R., Clark A.R., Venkat A.P., et al. The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. Br J Dermatol 152 (2005) 382-383
31. Fleischer Jr. A.B., Rapp S.R., Reboussin D.M., et al. Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol 102 (1994) 967-969
32. Fleischer Jr. A.B., Feldman S.R., and Dekle C.L. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 26 (1999) 210-215
33. Sampogna F., Sera F., Mazzotti E., et al. Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol 139 (2003) 353-358
34. Stata Corporation. Stata 8 reference manual (2003), College Station, TX
35. Stata Corporation. Stata Statistical Software: Release 8.0, Stata Corporation, College Station, TX. 2002.
36. Kline R.B. Principles and practice of structural equation modeling. 2nd ed. (2005), The Guilford Press, New York
37. Muthen, B. and Muthen, L. Mplus. Statistical analysis with latent variables. Version 3.12 for windows. 2004.
38. Tyring S., Gottlieb A., Papp K., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006) 29-35
39. Joinson A. Social desirability, anonymity, and Internet-based questionnaires. Behav Res Methods Instrum Comput 31 (1999) 433-438
40. Durant L.E., Carey M.P., and Schroder K.E. Effects of anonymity, gender, and erotophilia on the quality of data obtained from self-reports of socially sensitive behaviors. J Behav Med 25 (2002) 438-467
41. Kelley E., Moy E., Stryer D., et al. The national healthcare quality and disparities reports: an overview. Med Care 43 (2005) I3-I8
42. Moy E., Dayton E., and Clancy C.M. Compiling the evidence: the National Healthcare Disparities Reports. Health Aff (Millwood) 24 (2005) 376-387
43. Baker L., Wagner T.H., Singer S., and Bundorf M.K. Use of the Internet and e-mail for health care information: results from a national survey. JAMA 289 (2003) 2400-2406
44. Shikiar R., Bresnahan B.W., Stone S.P., et al. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 1 (2003) 53
45. Feldman S.R. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat 15 (2004) 27-29
46. Schmitt J., and Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210 (2005) 194-199
47. Richards H.L., Fortune D.G., Weidmann A., et al. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 151 (2004) 1227-1233
48. Picardi A., Abeni D., Melchi C.F., et al. Psychiatric morbidity in dermatological outpatients: an issue to be recognized. Br J Dermatol 143 (2000) 983-991
49. Picardi A., Amerio P., Baliva G., et al. Recognition of depressive and anxiety disorders in dermatological outpatients. Acta Derm Venereol 84 (2004) 213-217
50. Gupta M.A., and Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139 (1998) 846-850
51. Gupta M.A., Schork N.J., Gupta A.K., et al. Suicidal ideation in psoriasis. Int J Dermatol 32 (1993) 188-190